Glooko, Inc. and Hedia, today announced the launch of their interoperable solution, which combines connected care, remote ...
Bernstein analyst Lee Hambright raised the firm’s price target on Tandem Diabetes (TNDM) to $44 from $42 and keeps an Outperform rating on the ...
Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Insulin Pumps Market offers comprehensive insights into the market landscape, customer intelligence, ...
This research and delivery system will help patients with type 1 and type 2 diabetes receive their insulin based on real-time glucose levels.
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...
GlobalData on MSN15h
Glooko and Hedia launch joint diabetes management solutionGlooko’s integration of Hedia’s diabetes tech aims to improve care for patients and enhance healthcare provider insights.
Beta Bionics (BBNX), a maker of insulin delivery devices, has filed for a $100M initial public offering. While Beta Bionics ...
Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback